Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
As concerns over America’s fragile power grid grow, a little-known microcap, Duke Robotics (OTCQB: DUKR), is emerging as an innovative player to watch. The company’s drone technology clean and maintain high-voltage electric insulators, reducing the risk of blackouts at a time when grid reliability has become
2025 marked a turning point for Inspira Technologies (NASDAQ: IINN). The company’s FDA-cleared INSPIRA ART100 system, which delivers extracorporeal life support through advanced blood oxygenation, made the leap from concept to clinical use. In April 2025, physicians at Westchester Medical Center in New York completed the first successful
As Washington prepares for what could become the most significant federal cannabis reform in half a century, InterCure (NASDAQ:INCR) is quietly positioning itself ahead of the curve. A leading GMP-certified medical cannabis producer, the company is reinforcing its scientific foundation just as U.S. policy momentum accelerates. When
While precision medicine narrows its focus, this ~$357 million company may be developing a cancer treatment that could work across many accessible solid tumor types
With Big Pharma chasing injectable peptide blockbusters, Entera Bio’s tablet-based approach offers story in one of biotech’s hottest trends.
Digital health is entering a new phase, fueled by the GLP-1 revolution and employer cost pressure. With six enterprise contracts signed in October and a strategic review underway, DarioHealth sits at an inflection point between steady building and market recognition.
With an innovative technology addressing a crucial infection-prevention challenge, PolyPid’s technology could shift hospital incentives – and its ~$50M current market cap may position it as a bargain given it’s already validated with positive phase 3 results
After announcing a major new round of funding, DarioHealth Corp. (Nasdaq: DRIO) announced late last week that the company has initiated a comprehensive strategic review that could transform both the company and the digital health landscape, following multiple unsolicited inbound inquiries from interested parties. In other words, the company is
Sometimes the most explosive opportunities hide in plain sight. While investors chase household names, this tiny biotech just collected a milestone payment worth nearly 70% of its entire market cap – and this could be just the beginning.
InterCure’s Newly Announced Strategic Acquisition of ISHI Comes at Historic Inflection Point as Trump Administration Explores Cannabis Rescheduling
TL;DR: The global epinephrine market is set to double to $6-7 billion by 2030, and newly-public Nasus Pharma (NYSE: NSRX) is taking aim at the entire industry with an innovative powder technology that could make painful injections a thing of the past. As the company has just
Latest preclinical results validate systemic delivery approach, positioning SIL204 for Phase 2/3 initiation in first half of 2026
